

## 6 References

1. TECVAYLI (teclistamab-cqyv). Package insert. Janssen Biotech, Inc; 2022.
2. TECVAYLI (teclistamab). Summary of product characteristics. Janssen Biologics BV; 2022.
3. Palumbo A, Anderson K. Multiple myeloma. *N Engl J Med*. 2011;364:1046-1060.
4. van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. *Lancet*. 2021;397:410-427.
5. Noll JE, Williams SA, Tong CM, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. *Haematologica*. 2014;99:163-1S71.
6. Ravi P, Kumar SK, Cerhan JR, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. *Blood Cancer J*. 2018;8:26.
7. Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. *JAMA*. 2022;327:464-477.
8. de Mel S, Lim SH, Tung ML, Chng WJ. Implications of heterogeneity in multiple myeloma. *Biomed Res Int*. 2014;2014:232546.
9. Kamal M, Wang XS, Shi Q, et al. Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. *Support Care Cancer*. 2021;29:467-475.
10. Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. *Eur J Haematol*. 2016;97:416-429.
11. Ramsenthaler C, Osborne TR, Gao W, et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. *BMC Cancer*. 2016;16:427.
12. Schluterman KO, Fassas AB, Van Hemert RL, Harik SI. Multiple myeloma invasion of the central nervous system. *Arch Neurol*. 2004;61:1423-1429.
13. Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. *Blood Cancer J*. 2021;11:40.
14. National Cancer Institute. Cancer stat facts: myeloma. <https://seer.cancer.gov/statfacts/html/mulmy.html>. Accessed April 26 2023.
15. Mikhael J, Ismaila N, Cheung MC, et al. Treatment of multiple myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol*. 2019;37:1228-1263.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

16. Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P. Improving outcomes for patients with relapsed multiple myeloma: challenges and considerations of current and emerging treatment options. *Blood Rev.* 2021;49:100808.
17. Giannakoulas N, Ntanasis-Stathopoulos I, Terpos E. The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma. *Int J Mol Sci.* 2021;22:4462.
18. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer.* 2020;20:1087.
19. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood.* 2011;117:4691-4695.
20. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. *Leukemia.* 2022;36:1371-1376.
21. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia.* 2019;33:2266-2275.
22. Branagan A, Lei M, Lou U, Raje N. Current treatment strategies for multiple myeloma. *JCO Oncol Pract.* 2020;16:5-14.
23. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into future. *Haematologica.* 2020;105:2358-2367.
24. Heider M, Nickel K, Hogner M, Bassermann F. Multiple myeloma: molecular pathogenesis and disease evolution. *Oncol Res Treat.* 2021;44:672-681.
25. Michels TC, Petersen KE. Multiple myeloma: diagnosis and treatment. *Am Fam Physician.* 2017;95:373-383.
26. Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. *J Clin Oncol.* 2016;34:1544-1557.
27. Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. *Cancer Growth Metastasis.* 2014;7:33-42.
28. Egan PA, Elder PT, Deighan WI, O'Connor SJM, Alexander HD. Multiple myeloma with central nervous system relapse. *Haematologica.* 2020;105:1780-1790.
29. Jurczynszyn A, Grzasko N, Gozzetti A, et al. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. *Am J Hematol.* 2016;91:575-580.
30. CARVYKTI (ciltacabtagene autoleucel). Package insert. Janssen Biotech, Inc.; 2022.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

31. ABECMA (idecabtagene vicleucel). Package insert. Bristol-Myers Squibb Company; 2021.
32. THALOMID (thalidomide). Prescribing information. Celgene Corporation; February 2021.
33. REVLIMID (lenalidomide). Prescribing information. Celgene Corporation; August 2021.
34. POMALYST (pomalidomide). Prescribing information. Celgene Corporation; December 2020.
35. VELCADE (bortezomib). Prescribing information. Takeda Pharmaceuticals America, Inc.; November 2021.
36. KYPROLIS (carfilzomib). Prescribing information. Amgen, Inc.; November 2021.
37. NINLARO (ixazomib). Prescribing information. Takeda Pharmaceutical Company Limited; March 2021.
38. SARCLISA (isatuximab-irfc). Prescribing information. Sanofi-Aventis U.S. LLC; March 2021.
39. Devarakonda S, Efebera Y, Sharma N. Role of stem cell transplantation in multiple myeloma. *Cancers (Basel)*. 2021;13:863.
40. EMLICITI (elotuzumab). Package insert. Bristol-Myers Squibb Company; 2015.
41. DARZALEX (daratumumab). Prescribing information. Janssen Biotech, Inc.; March 2022.
42. Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. *Ther Adv Hematol*. 2018;9:123-133.
43. Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient. *Hematology Am Soc Hematol Educ Program*. 2017;2017:498-507.
44. Ackley J, Ochoa MA, Ghoshal D, Roy K, Lonial S, Boise LH. Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma. *Cancers (Basel)*. 2021;13:4787.
45. Holstein SA, McCarthy PL. Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. *Drugs*. 2017;77:505-520.
46. Ito S. Proteasome inhibitors for the treatment of multiple myeloma. *Cancers (Basel)*. 2020;12:375-386.
47. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med*. 2015;372:142-152.
48. Lapietra G, Fazio F, Petrucci MT. Race for the cure: from the oldest to the newest monoclonal antibodies for multiple myeloma treatment. *Biomolecules*. 2022;12:1146.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

49. van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. *Front Immunol.* 2018;9:2134.
50. XPOVIO (selinexor) tablets. Package insert. Karyopharm Therapeutics Inc; 2019.
51. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med.* 2019;381:727-738.
52. Nijhof IS, van de Donk N, Zweegman S, Lokhorst HM. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. *Drugs.* 2018;78:19-37.
53. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. *Mol Ther Oncolytics.* 2016;3:16015.
54. Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. *Biomark Res.* 2017;5:22.
55. Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med.* 2021;384:705-716.
56. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. *J Clin Oncol.* 2023;41:1265-1274.
57. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet.* 2021;398:314-324.
58. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia.* 2020;34:985-1005.
59. Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. *Blood Adv.* 2020;4:4538-4549.
60. Alhallak K, Sun J, Jeske A, et al. Bispecific T cell engagers for the treatment of multiple myeloma: achievements and challenges. *Cancers (Basel).* 2021;13:2853.
61. Lejeune M, Köse MC, Duray E, Einsele H, Beguin Y, Caers J. Bispecific, T-cell-recruiting antibodies in B-cell malignancies. *Front Immunol.* 2020;11:762.
62. Zhou X, Einsele H, Danhof S. Bispecific antibodies: a new era of treatment for multiple myeloma. *J Clin Med.* 2020;9:2166.
63. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. *Br J Haematol.* 2016;175:252-264.
64. Castaneda-Puglianini O, Chavez JC. Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma. *Drugs Context.* 2021;10:2021-2-4.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

65. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. *Front Immunol*. 2018;9:1821.
66. Soekojo CY, Ooi M, de Mel S, Chng WJ. Immunotherapy in multiple myeloma. *Cells*. 2020;9:601.
67. Wang Q, Chen Y, Park J, et al. Design and production of bispecific antibodies. *Antibodies (Basel)*. 2019;8:43.
68. Bonello F, Mina R, Boccadoro M, Gay F. Therapeutic monoclonal antibodies and antibody products: current practices and development in multiple myeloma. *Cancers (Basel)*. 2019;12:15.
69. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. *CPT Pharmacometrics Syst Pharmacol*. 2017;6:576-588.
70. Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. *Drug Des Devel Ther*. 2018;12:195-208.
71. Hill E, Morrison C, Kazandjian D. Daratumumab: a review of current indications and future directions. *Semin Oncol*. 2022;49:48-59.
72. Gozzetti A, Ciofini S, Simoncelli M, et al. Anti CD38 monoclonal antibodies for multiple myeloma treatment. *Hum Vaccin Immunother*. 2022;18:2052658.
73. Bashash D, Zandi Z, Kashani B, Pourbagheri-Sigaroodi A, Salari S, Ghaffari SH. Resistance to immunotherapy in human malignancies: mechanisms, research progresses, challenges, and opportunities. *J Cell Physiol*. 2022;237:346-372.
74. Saltarella I, Desantis V, Melaccio A, et al. Mechanisms of resistance to anti-CD38 daratumumab in multiple myeloma. *Cells*. 2020;9:167.
75. Torka P, Barth M, Ferdman R, Hernandez-Ilizaliturri FJ. Mechanisms of resistance to monoclonal antibodies (mAbs) in lymphoid malignancies. *Curr Hematol Malig Rep*. 2019;14:426-438.
76. Goldschmidt H, Ashcroft J, Szabo Z, Garderet L. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? *Ann Hematol*. 2019;98:1-18.
77. Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. *Clin Cancer Res*. 2013;19:2048-2060.
78. Cho SF, Lin L, Xing L, et al. BCMA-targeting therapy: driving a new era of immunotherapy in multiple myeloma. *Cancers (Basel)*. 2020;12:1473.
79. Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. *Clin Cancer Res*. 2013;19:1917-1919.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

80. Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. *J Hematol Oncol*. 2020;13:125.
81. Laurent SA, Hoffmann FS, Kuhn PH, et al. gamma-Secretase directly sheds the survival receptor BCMA from plasma cells. *Nat Commun*. 2015;6:7333.
82. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. *Immunotherapy*. 2015;7:1187-1199.
83. Moreau P. Updated results from MajesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. Presented at: the 63rd American Society of Hematology (ASH) Annual Meeting; December 11–14, 2021; Atlanta, GA/Virtual.
84. Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. *EBioMedicine*. 2020;52:102625.
85. Hutchings M, Mous R, Clausen MR, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. *Lancet*. 2021;398:1157-1169.
86. Strohl WR, Naso M. Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells. *Antibodies (Basel)*. 2019;8:41.
87. Frerichs KA, Broekmans MEC, Marin Soto JA, et al. Preclinical activity of JNJ-7957, a novel BCMA×CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. *Clin Cancer Res*. 2020;26:2203-2215.
88. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. *N Engl J Med*. 2022;387:495-505.
89. Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. *Lancet*. 2021;398:665-674.
90. Johnson & Johnson. Janssen announces U.S. FDA breakthrough therapy designation granted for teclistamab for the treatment of relapsed or refractory multiple myeloma. [https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-teclistamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma#\\_edn1](https://www.jnj.com/janssen-announces-u-s-fda-breakthrough-therapy-designation-granted-for-teclistamab-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma#_edn1). Accessed May 30 2023.
91. Nooka AK. Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): updated efficacy and safety results from MajesTEC-1 Presented at: the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL/Virtual.
92. Jagosky MH, Usmani SZ. Extramedullary disease in multiple myeloma. *Curr Hematol Malig Rep*. 2020;15:62-71.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

93. Brioli A, Klaus M, Sayer H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. *Ann Hematol*. 2019;98:713-722.
94. Martin TG, Mateos MV, Nooka A, et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. *Cancer*. 2023;
95. Cortes-Selva D. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: correlative analyses from MajesTEC-1. Presented at: the 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.
96. Touzeau C. Efficacy and safety of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma after exposure to other BCMA-targeted agents. Presented at: the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL/Virtual.
97. Rodriguez-Otero P. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for daratumumab in combination with teclistamab (a B-cell maturation antigen × CD3 bispecific antibody). Presented at: the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL/Virtual.
98. Mateos MV. MajesTEC-3: randomized phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. Presented at: the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL/Virtual.
99. European Medicines Agency. New medicine for multiple myeloma patients with limited treatment options. European Medicines Agency. <https://www.ema.europa.eu/en/news/new-medicine-multiple-myeloma-patients-limited-treatment-options>. Accessed May 30 2023.
100. US Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. US Food and Drug Administration; 2022.
101. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. *Blood*. 2004;103:3148-3157.
102. Neri P, Kumar S, Fulciniti MT, et al. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. *Clin Cancer Res*. 2007;13:5903-5909.
103. Moreau P, van de Donk N, Delforge M, et al. Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and/or refractory multiple myeloma. *Adv Ther*. 2023;40:2412-2425.

TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

104. Krishnan A. Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma [published online ahead of print, 2023 Apr 28]. *J Comp Eff Res*. 2023;e220186.
105. Mateos MV. Adjusted comparison of teclistamab versus physician's choice of therapy in the long-term follow-up of daratumumab trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Presented at: the 19th International Myeloma Society (IMS) Annual Meeting; August 25–27, 2022; Los Angeles, CA.
106. Moreau P. Matching-adjusted indirect treatment comparison of teclistamab vs approved therapies for the treatment of patients with triple-class exposed relapsed/refractory multiple myeloma. Presented at: the 19th International Myeloma Society (IMS) Annual Meeting; August 25–27, 2022; Los Angeles, CA.
107. Engelhardt M, Ihorst G, Singh M, et al. Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. *Clin Lymphoma Myeloma Leuk*. 2021;21:e160-e175.
108. Martin T. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with teclistamab, a B-cell maturation antigen x CD3 bispecific antibody: patient-reported outcomes in MajesTEC-1. Presented at: the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3–7, 2022; Chicago, IL/Virtual.
109. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. *Blood*. 2016;128:384-394.
110. Zamagni E. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab + lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Presented at: the 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.
111. Cohen YC, Oriol A, Wu KL, et al. Daratumumab with cetrelimab, an anti-PD-1 monoclonal antibody, in relapsed/refractory multiple myeloma. *Clin Lymphoma Myeloma Leuk*. 2021;21:46-54.e4.
112. Chari A. Talquetamab, a G protein-coupled receptor family C group 5 member D × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: phase 1/2 results from MonumentAL-1. Presented at: the 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.
113. Fernandez de Larrea C, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted car t-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. *Blood Cancer Discov*. 2020;1:146-154.
114. Searle E. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1b, multicohort study. Presented at: the 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.



TECVAYLI™ (teclistamab-cqyv) US Prix Galien submission. June 26, 2023.

115. Krishnan A. MajesTEC-7: a phase 3, randomized study of teclistamab + daratumumab + lenalidomide versus daratumumab + lenalidomide + dexamethasone in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant. Presented at: the 64th American Society of Hematology (ASH) Annual Meeting; December 10–13, 2022; New Orleans, LA.
116. Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. *Blood Cancer J*. 2019;9:10.
117. Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. *Acta Pharm Sin B*. 2018;8:539-551.
118. Anderson LD, Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. *Future Oncol*. 2022;18:277-289.
119. Kourelis T, Bansal R, Berdeja J, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. *Transplant Cell Ther*. 2023;29:255-258.
120. Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. *BioDrugs*. 2018;32:425-440.
121. Sanchez-Felix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. *Adv Drug Deliv Rev*. 2020;167:66-77.
122. Slavcev M, Spinelli A, Absalon E, et al. Results of a time and motion survey regarding subcutaneous versus intravenous administration of daratumumab in patients with relapsed or refractory multiple myeloma. *Clinicoecon Outcomes Res*. 2021;13:465-473.
123. Barbee MS, Harvey RD, Lonial S, et al. Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences. *Ann Pharmacother*. 2013;47:1136-1142.
124. Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. *Lancet Haematol*. 2020;7:e370-e380.